Baseline characteristics of patients who received RIT and BEAM based Stem Cell Transplant
| Characteristic . | N (%) or median (range) . |
|---|---|
| Sex | |
| Female | 7 (35) |
| Male | 13 (65) |
| Age (y) at initial treatment | 51 (18-76) |
| Ethnicity | |
| Hispanic | 5 (25) |
| White | 4 |
| Asian/Pacific Islander | 1 |
| Non-Hispanic | 15 (75) |
| Race/ethnicity | |
| White | 12 (60) |
| Asian | 2 (10) |
| Black | 5 (25) |
| Multiple race (Asian/Pacific Islander) | 1 (5) |
| Diagnosis | |
| PTCL-NOS | 10 (50) |
| Angioimmunoblastic T-cell lymphoma | 3 (15) |
| ALK-ve ALCL | 5 (25) |
| Intestinal T-cell lymphoma | 2 (10) |
| Stage at diagnosis | |
| I | 2 (10) |
| II | 3 (15) |
| III | 4 (20) |
| IV | 11 (55) |
| Disease status before the study treatment | |
| CR1 | 18 (90) |
| CR2 | 2 (10) |
| Chemosensitivity before the study treatment | |
| Resistant | 0 (0) |
| Sensitive | 20 (100) |
| Performance status at transplant | |
| 90 | 10 (50) |
| 100 | 10 (50) |
| Number of prior therapies | 1 (1-4) |
| Prior radiation therapy | |
| No | 19 (95) |
| Yes | 1 (5) |
| Prior treatments | |
| CHOP | 5 |
| CHOEP | 8 |
| EPOCH | 3 |
| A + CHP | 1 |
| ABVD | 1 |
| Newcastle regimen | 1 |
| Other | 1 |
| Salvage treatments | |
| Brentuximab vedotin | 3 |
| Gemcitabine based | 1 |
| Characteristic . | N (%) or median (range) . |
|---|---|
| Sex | |
| Female | 7 (35) |
| Male | 13 (65) |
| Age (y) at initial treatment | 51 (18-76) |
| Ethnicity | |
| Hispanic | 5 (25) |
| White | 4 |
| Asian/Pacific Islander | 1 |
| Non-Hispanic | 15 (75) |
| Race/ethnicity | |
| White | 12 (60) |
| Asian | 2 (10) |
| Black | 5 (25) |
| Multiple race (Asian/Pacific Islander) | 1 (5) |
| Diagnosis | |
| PTCL-NOS | 10 (50) |
| Angioimmunoblastic T-cell lymphoma | 3 (15) |
| ALK-ve ALCL | 5 (25) |
| Intestinal T-cell lymphoma | 2 (10) |
| Stage at diagnosis | |
| I | 2 (10) |
| II | 3 (15) |
| III | 4 (20) |
| IV | 11 (55) |
| Disease status before the study treatment | |
| CR1 | 18 (90) |
| CR2 | 2 (10) |
| Chemosensitivity before the study treatment | |
| Resistant | 0 (0) |
| Sensitive | 20 (100) |
| Performance status at transplant | |
| 90 | 10 (50) |
| 100 | 10 (50) |
| Number of prior therapies | 1 (1-4) |
| Prior radiation therapy | |
| No | 19 (95) |
| Yes | 1 (5) |
| Prior treatments | |
| CHOP | 5 |
| CHOEP | 8 |
| EPOCH | 3 |
| A + CHP | 1 |
| ABVD | 1 |
| Newcastle regimen | 1 |
| Other | 1 |
| Salvage treatments | |
| Brentuximab vedotin | 3 |
| Gemcitabine based | 1 |
ABVD, Adriamycin, Bleomycin, vinblastin, Dacarbazine; ALK-ve, Peripheral T cell lymphoma; CHOP, Cytoxan adriamycin, vincristine prednisone; CHOEP, Cytoxan, Etoposide adriamycin, vincristine prednisone; EPOCH, etoposide Cytoxan, Etoposide adriamycin, vincristine prednisone; A+CHP, Brentuximab vedotin + cytoxan adriamycin, prednisone; NOS, not otherwise specified.